B - 46 Diagnostic Utility of Conners CPT-3 for ADHD: a Systematic Review.

Abstract

There is ongoing debate about the diagnostic utility of Conners Continuous Performance Test 3 (CPT-3) for attention deficit/hyperactivity disorder (ADHD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, 2020) reporting standards, a systematic review was conducted. Six bibliographic databases including MEDLINE, PsycINFO, and PsycARTICLES were searched using terms related to continuous performance tests and ADHD in January 2022 and again in October 2022. Inclusion criteria included research studies published since 2000, English language, and ages 8+. Screening was conducted independently by two reviewers, with 1480 title/abstracts reviewed followed by 399 full text articles. Any discrepancies were resolved by a third reviewer. A data extraction template was developed and piloted and critical appraisal of included studies was conducted using the Quality Assessment Tool for Quantitative Studies. Study results were analyzed using reflective thematic analysis through inductive coding (Braun & Clarke, 2006, 2019). Thirteen studies met the criteria and five qualitative themes were identified. Five studies found CPT-3 was a weak or poor predictor of the diagnosis of ADHD while two found it as an adequate predictor. Two studies found the CPT-3 could differentiate clients with comorbid ADHD/anxiety from ADHD or ADHD from obsessive-compulsive disorder. One study, however, found that CPT-3 could not differentiate ADHD from autism spectrum disorder (ASD) or comorbid ADHD/ASD. This systematic review revealed that CPT-3 as a standalone measure is a weak or poor predictor of ADHD and clinicians are recommended to use multiple measures for evaluating persons with ADHD.